CA3027048A1 - Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes - Google Patents

Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes Download PDF

Info

Publication number
CA3027048A1
CA3027048A1 CA3027048A CA3027048A CA3027048A1 CA 3027048 A1 CA3027048 A1 CA 3027048A1 CA 3027048 A CA3027048 A CA 3027048A CA 3027048 A CA3027048 A CA 3027048A CA 3027048 A1 CA3027048 A1 CA 3027048A1
Authority
CA
Canada
Prior art keywords
formulation
diabetes
composition
cells
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3027048A
Other languages
English (en)
French (fr)
Inventor
Horacio ASTUDILLO DE LA VEGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of CA3027048A1 publication Critical patent/CA3027048A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3027048A 2015-06-08 2017-06-08 Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes Pending CA3027048A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 2016-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
MXMX/A/2017/007448 2017-06-07
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (1)

Publication Number Publication Date
CA3027048A1 true CA3027048A1 (en) 2017-12-14

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027048A Pending CA3027048A1 (en) 2015-06-08 2017-06-08 Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JPWO2008143182A1 (ja) * 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Also Published As

Publication number Publication date
RU2018147077A3 (enExample) 2020-09-21
ES2988151T3 (es) 2024-11-19
CN109890369B (zh) 2022-04-29
JP2019521184A (ja) 2019-07-25
BR112018075395A2 (pt) 2019-04-02
US10285963B2 (en) 2019-05-14
MX365886B (es) 2019-06-19
CN109890369A (zh) 2019-06-14
US20160354331A1 (en) 2016-12-08
RU2018147077A (ru) 2020-07-10
RU2749950C2 (ru) 2021-06-21
MX2017007448A (es) 2018-09-10

Similar Documents

Publication Publication Date Title
Scarian et al. New insights into oxidative stress and inflammatory response in neurodegenerative diseases
Vinayagamoorthi et al. Antioxidants preserve redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance
Pandey et al. Antioxidant and anti-aging potential of Juniper berry (Juniperus communis L.) essential oil in Caenorhabditis elegans model system
Talagavadi et al. Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK/mTOR/S6K pathway and improve glucose homeostasis in mice
Lei et al. The antioxidant effect of Asparagus cochinchinensis (Lour.) Merr. shoot in D-galactose induced mice aging model and in vitro
Zhou et al. Tetrahydroxystilbene glucoside extends mouse life span via upregulating neural klotho and downregulating neural insulin or insulin-like growth factor 1
CA2917712A1 (en) Compositions prepared from poultry and methods of their use
US10039798B2 (en) Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm
Lee Regulation of cytochrome c oxidase by natural compounds resveratrol,(–)-epicatechin, and betaine
Han et al. (‐)‐Hydroxycitric acid nourishes protein synthesis via altering metabolic directions of amino acids in male rats
Scorza et al. Exploring the prospective role of propolis in modifying aging hallmarks
JP6510004B2 (ja) イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
US10285963B2 (en) Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
Niewiadomska et al. Effects of Punica granatum L. peel extract supplementation on body weight, cardiac function, and haematological and biochemical parameters in an animal model of metabolic syndrome
EP3470060B1 (en) Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
Emami et al. Effects of high intensity interval training and curcumin supplement on glutathione peroxidase (GPX) activity and malondialdehyde (MDA) concentration of the liver in STZ induced diabetic rats
Zhong et al. Tea catechins protect goat skeletal muscle against H2O2-induced oxidative stress by modulating expression of phase 2 antioxidant enzymes
OA19128A (en) Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes.
Kasem et al. Ameliorative effect of N acetyl cysteine against diclofenac-induced oxidative stress, hematological and splenic toxicity in male rats
HK40010029A (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
HK40010029B (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
Roxo et al. The use of the nematode Caenorhabditis elegans to study antioxidant and longevity-promoting plant secondary metabolites
Mohammed et al. Anti-diabetic efficacy of young and mature leaf extract of Mangifera indica
Turska et al. A Review of the Health Benefits of Food Enriched with Kynurenic Acid. Nutrients 2022, 14, 4182
Ding et al. Dietary propionate induces intestinal oxidative stress via inhibition of SIRT3-mediated SOD2 depropionylation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221111

EEER Examination request

Effective date: 20221111

EEER Examination request

Effective date: 20221111

EEER Examination request

Effective date: 20221111